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HERSH, L B , N. ABOUKHAIR AND S WATSON Immunohtsto{hemlcal locahzatlon ofamtnopepttdase M in rat 
brain and pertphery Relationship of enzyrne Io~ ahzatlon and enhephahn metabolism. PEPTIDES 8(3) 523-532, 1987 --An 
antiserum specific for rat ammopeptadase M has been used for the ammunohistochemlcal localizatmn of the enzyme m rat 
brain and peripheral tissues. The enzyme m brain is localized exclusively on blood vessels. Within the pituitary the enzyme 
was assocmted with the vasculature m the postermr lobe, on the surface of the mtermedmte lobe and on the surface of some 
cells in the anterior lobe In the laver, fine cell staining was observed between parenchymal cells, m the deum the entire 
lumenal surface was stained, whde m the kadney both proximal tubular and a central tubular stammg was detected In each 
tissue ammopepudase M as localized such that it can hmlt d~ffUSlOn across spemfic bamers Amlnopeptldase M activity m 
brain has been proposed to functmn in the degradation of synaptmally released enkephahns. Its localizatmn on blood 
vessels reqmres that enkephalms daffuse pnor to degradatmn, a concept not m concert w~th current hypotheses Based on 
these studies at is proposed that &ffusmn away from enkephahnerglc synapses plays a key role m terminating enkephalm 
action 
Amlnopept~dase M Immunoh~stochemlstry Enkephahn degradation m brain 
IT is currently beheved that the physiological action of 
synaptically released enkephalins is terminated by enzyma- 
tic degradation [12, 21, 22]. Two peptidase activities have 
been ~dentified in synaptic membrane preparations which 
could act as "enkephal inases" m vtvo. One of these is a 
neutral metalloendopeptidase which cleaves enkephalins at 
the Gly-Phe bond, while the other is an aminopeptidase 
which cleaves at the Tyr-Gly bond of the enkephalins [12, 21, 
22]. 
Two membrane bound aminopeptldases were identified in 
rat synaptic membrane preparations and designated MI and 
MII [11,13]. Aminopeptidase MII exhibits a broad substrate 
specifimty with regard to amino acid beta naphthylamides 
and has been shown to represent the major enkephalin de- 
grading ammopeptidase activity in brain homogenates [11]. 
Its distribution in rat brain approximates the distribution of 
enkephalin receptors [13]. The enzyme is inhibited by the 
classmal aminopeptidase inhibitor bestatm but can be distin- 
gmshed from other membrane aminopept~dases by its sen- 
sitivlty to inhibition by puromycin [11,13]. 
Although this enzyme appeared to represent the major 
aminopeptldase which could act as an "enkephal inase" in 
vivo, several studies have raised questions concerning the 
role of aminopeptldase MII in degrading synaptically re- 
leased enkephalins. Using brain shces it was shown that in- 
dividually the neutral endopeptidase inhibitor thiorphan and 
the general aminopeptidase inhibitor bestatin could protect 
endogenous enkephalins, released by potassium depolariza- 
tion, against degradation [5,6]. Together these inhibitors af- 
forded almost complete protection against enkephalin degra- 
dation. In addition these mhibitors alone or m combination 
produced an analgesm effect m mice However,  the 
aminopeptldase MII inhibitor puromycin, which is relatively 
specific for this enzyme, was ineffective in protecting 
synaptically released enkephalins from degradation and did 
not elicit an analgesic response in experimental ammals [3, 5, 
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6] However in another study [10] puromycm produced a 
dose-related, naloxone reversible analgesia in rats which was 
accompanied by an increase in striatal enkephalin levels. 
An apparent solution to this confusion was the recent 
finding of aminopeptidase M activity in rat brain synaptlc 
membrane preparations [8, 9, 17]. This enzyme was sepa- 
rated from aminopeptidase MII by either chromatography on 
conA-sepharose [8,9] or by phase separation using Triton 
X-II4 [17]. Aminopeptidase M (APM) activity comprised 
approximately 5% of the total membrane aminopeptidase 
activity. The enzyme hydrolyzes enkephalins with a Km of 
45 /~M It is potently inhibited by bestatm (KI=4/zM),  but 
poorly inhibited by puromycin (Ki= 100/zM). By comparison 
aminopeptidase MII exhibits a Kl of 0.5/xM for bestatin and 
a KI of 1 /~M for puromycin. Both of these aminopeptidases 
can be distinguished from aminopeptidase MI [11] The latter 
enzyme is specific for basic aminoacld beta naphthylamldes, 
is considerably less sensitwe to puromycm (KI= 1 mM), and 
does not hydrolyze enkephalins at an appreciable rate [8]. 
Thus if aminopeptldase M could be shown to exist at 
enkephalinerglc synapses or in the neuropile of enkephahn 
rich areas its involvement m the degradation of synaptically 
released enkephalins would be more firmly established. In 
the present paper we report the results of immunohlstochem- 
Ical studies on the localization of ammopeptidase M m rat 
brain and selected peripheral tissues. 
METHOD 
Purifi~ atton oJ Ammopepttda~e M 
Ammopeptldase M was purified from rat kidney using a 
modification of the procedure used by Gros et al. [8]. Rat 
kidneys were homogenized in 10 volumes of 50 mM Tris-HCl 
buffer, pH 7.5. The membrane fraction was obtained as de- 
scribed [8] and solubllized by resuspension in a volume of 50 
mM Tns-HC1, pH 7.5 containing 1% Triton X-100 equal to 
the original weight of tissue. After stirring for 1 hour at room 
temperature, the material was centrifuged at 100,000 × g for 
1 hour. To the 100,000 × g supernatant was added MgCI.,, 
MnCl2, and CaCI.., to a final concentration of 1 mM and 
2-mercaptoethanol to a final concentration of 5 mM. The 
enzyme was then chromatographed on Con A-Sepharose and 
DEAE-cellulose as described by Gros et al. [8] Starting with 
50 g or rat kidney 1.6 mg of essentially homogeneous enzyme 
was obtained. 
A,s say of Aminopepttdase A~ ttvttv 
Aminopeptidase activity was measured with alanme 
beta-naphthylamide as substrate as previously described 
[13]. Reaction mixtures contained 0.2 mM alanlne beta- 
naphthylamlde, 50 mM Tris-HC1 buffer, pH 7.4, and enzyme 
m a final volume of 250/zl. Protein was determined by the 
method of Bradford [1]. 
Ammopepttda~e M Anttsera 
The anti-rat kidney ammopeptidase M antisera used m 
these studies was that prepared by Tsao and Curthoys [24] 
and provided to us as a generous gift. 
Immttnoht~ tochemt.s In 
Amlnopeptldase M ,mmunohistochemistry was con- 
ducted by standard procedures [23]. Male Sprague-Dawley 






2 A  
3 4 
IMMUNOBLOT ANALYSIS 




1 3 4 
FIG 1 Immunoblot detection of rat kidney and rat brain amlnopep- 
tldase M Ammopeptldase M from vanous samples of rat kidney or 
rat brain was subjected to SDS-PAGE and eaher sta,ned for protein 
with Coomassle Blue or electrophoretlcally transferred to mtrocel- 
lulo,se and vlsuahzed w~th antJ-ammopeptldase M antlsera The 
samples tested were as follows Lane 1--20/zg of crude rat kidney 
homogenate Lane 2--2 tzg of purified rat kzdney APM Lane 3--20 
/zg of rat brain homogenate Lane 4--10 ~tg of rat brain ammopep- 
tldase M eluted from con A-sepharose 
/xg/10 /zl of normal sahne) in the lateral ventricle. After 48 
hours of colchlcine treatment the rats were perfused w~th 4%, 
neutral buffered formaldehyde. The brains were removed 
and postfixed for 1 hour in 4% formaldehyde, immersed m 
15% sucrose overnight and then frozen in hquid nitrogen. 
The t~ssue was cryostat sectioned at 10 /zM and mounted 
onto gelatin subbed slides. Aminopeptzdase M antiserum 
was used at tlters ranging from 1/100 to 1/1,000 on whole 
coronal sections taken throughout rat brain. Sections were 
taken in a similar fashion from pituitary, ileum, kidney and 
liver Tissue sections were Incubated overnight at 4°C with 
the APM antisera, then washed in phosphate buffered saline 
(PBS). Goat anti rabbit serum was applied to the tissue and 
sections incubated overnight at 4°C The tmsue was washed 
in PBS, incubated at 37°C for 40 minutes with rabbit anti 
horseradish peroxldase (HRP), washed again m PBS and 
then incubated at 37°C for 40 minutes with 4 /zg/ml HRP 
enzyme. After completion of this step the slides were im- 
mersed m a solution of 0.125 mg/ml diaminobenmdine tet- 
rahydrochlonde and 0.03% H202 for 15 minutes The tissue 
was then washed for 30 minutes m water immersed in 2% 
OsO4 briefly, dehydrated and mounted in Permount. Obser- 
vations were made on a Leitz Orthoplan Microscope. 
Blocking competition studies, using purified rat kidney 
amlnopeptidase M enzyme (2.5 mg/ml), were carried out at 
two antiserum concentrations (1/100 and 1/1,000) and at sev- 
eral enzyme concentrations (12.5/.tg, 2.5 ttg, 0.5/zg, 0.25/zg, 
0 025 /zg, per 100 ~1 Incubation volume). Thirty minutes 
prior to addition of serum to the section, enzyme solution 
was added to antiserum. A parallel control study with 
enzyme buffer only was carried out with the same volumes 
as the 12.5 ~g concentration of enzyme. 
Other Method~ 
SDS-PAGE and immunoblot analysis was conducted as 
previously described [2]. 
RESULTS 
The presence of aminopeptidase M actwlty in brain has 
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FIG. 2. Paraventrlcular nucleus of hypothalamus (PVN) was stained by APM antiserum at 1/100 dilution. Panel A shows four distinct 
features--a darkly stained ependymal lining, darkly stained blood vessels and lightly stained neuroplle and nuclei Panels B and C show 
blocking with mcreasmg concentrations of purified APM protein (0 5/zg and 12.5/~g of APM protein). Neither blocking control shows changes 
In nuclear or neuroplle staining, while partial loss of ependymal and complete loss of vascular staining is found in Panel C. Cahbratlon bar 
Panel A=50/zm, Panels B and C=200/xm (v=thlrd ventricle) 
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FIG 3 Same treatment as Fig 1 except  that the PVN is stained with APM annserum at 1/1,000 dilution At this concentration, Panel 
A shows  only vascular staining, while 0 25 /zg and 12 5 /zg of APM protein (Panels B and C) increasingly blocked that stare 
Cahbratlon bar Panel A = 5 0  # m  (v=thlrd ventricle) 
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FIG 4. Caudate and corpus callosal areas are stained by APM antiserum at 1/100 ddution Panel A shows heavy vascular (single 
arrow) and light neuroplle (double arrow) staining As in Figs 1 and 2, 0.5 ~g and 12.5 p.g of APM protein increasingly blocked the 
vascular stain but not that found m the neuropile Cahbratnon bar Panel A=50/~m,  Panel B=100/~m, Panel C=50/~m 



















FIG. 5 Caudate and corpus callosal areas stained by APM antiserum at 1/1000. Panel A shows the hght neuroplle (double arrows) 
and heavy vascular stain (single arrow). Panel B and C show increasing blockade of the vascular staining, but not the neuroplle, with 
APM protein. Calibration bar Panel A=50 /zm,  Panel B and C= 100/zm. 
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recently been demonstrated by Gros et al. [8,9] and by Mat- 
sas et al. [17]. We have confirmed this observation using Con 
A-Sepharose to resolve aminopeptidase M from aminopep- 
tidase MII activity as described by Gros et al. [8]. 
Aminopeptidases MI and MII do not bind to Con A- 
Sepharose,  while amlnopeptidase M activity is retained by 
Con A-Sepharose and subsequently eluted with 0.2 M 
methyl alpha-D-mannoside. Approximately 3% of the total 
aminopeptldase activity obtained from a Triton extract of rat 
brain membranes is attributable to amlnopeptidase M activ- 
ity when assayed with alanine beta-naphthylamide as a sub- 
strate. To confirm that the aminopeptidase activity bound to 
Con A-Sepharose is indeed aminopeptidase M, the ability of 
an anti-rat kidney aminopeptidase M antiserum to inhibit this 
activity was examined. This antisera showed essentially the 
identical inhibition curve with rat kidney aminopeptidase M 
as with the putative rat brain aminopeptidase M activity. No 
inhibition of  aminopeptidase MII activity was observed with 
this antisera. Adsorption of the antisera with purified rat 
kidney aminopeptidase M abolished both the ability of the 
antisera to inhibit both the brain and kidney activities as well 
as the ability to visualize either protem by immunoblotting. 
In addition 25/zM puromycln inhibited aminopeptidase MII 
activity more than 90% while aminopeptidase M activity was 
inhibited less than 20% at this concentration of puromycin. 
Both kidney and brain aminopeptldase M activities were 
inhibited greater than 90% with 15 /xM bestatin. These re- 
sults serve to establish the identity of the kidney and brain 
aminopeptidase M. 
The speoficl ty of the anti-aminopeptldase M antisera was 
exammed by immunoblot analysis. As shown in Fig. 1 this 
antiserum brads to only a single protein in a crude rat kidney 
homogenate which corresponds to the purified enzyme. The 
level of aminopeptidase activity in brain ~s too low to be 
detected in a crude homogenate by immunoblot analysis. 
However  we were able to visualize a partially purified prep- 
aration of  the rat brain enzyme. The absence of any detecta- 
ble immunoreactivity with a crude rat brain homogenate as 
well as the finding that only amlnopeptldase M reacts with 
the antiserum in a crude kidney homogenate demonstrates 
that this antiserum is monospeclfiC for aminopeptidase M 
and exhibits no cross-reactivity with any proteins found in 
rat brain. Based on the above experiments this antiserum 
was judged suitable for immunohistochemical visualization 
of  the enzyme in rat brain. 
The anti aminopeptldase M antiserum stained rat brain at 
concentrations up to (1/1,000). At 1/100 the staining of  brain 
was composed of three types of signals, modest  nuclear and 
cytoplasmic stains throughout the neuropile, and a denser 
stain surrounding all blood vessels (Figs. 2 and 4). There was 
no obvious preference of particular brain regions, as all 
seemed positive. At 1/1,000, only the vascular staining could 
be detected (Figs. 3 and 5). Because colchicine pretreatment 
was indistinguishable from untreated rats, all data are on 
normal, untreated rats. 
Because it was unclear which of  the staining patterns was 
specific (vascular, nuclear or cytoplasmic) we carried out 
solution-phase competit ion studies at 1/100 and at 1/1,000 
antibody dilution. At  1/100 the enzyme buffer solution did 
not alter the staining patterns. However  12.5 ~zg of  APM 
enzyme (and 2.5/xg of APM enzyme) completely blocked all 
vascular staining without obviously effectlng the nuclear and 
cytoplasmic staining (Figs. 2C and 4C). At 0.5 p.g of APM 
enzyme, return of faint vascular staining was detected (Figs 
2B and 4B), with increasingly clear staining as the concen- 
tration of  antigen dropped (0.25 /zg, 0.025 ~g). At 1/1,000 
tlter the buffer had no effect on the only staining in the sec- 
tion (around the vasculature). All staining was blocked at 
12.5/~g, 2.5/xg and 0.5 p~g of  APM enzyme (Figs. 3C and 5C) 
beginning to return at 0.25/zg (Figs. 3B and 5B) and increas- 
ing as the antigen concentrahon dropped. Thus specific, 
blockable staining was only detected in the region of brain 
vasculature and not in the nuclei, cytoplasm or the 
neuroplle. Beyond the vasculature the other set of appar- 
ently stained structures included the chorold plexus, epen- 
dyma and dura. After blocking it became clear the choroid 
plexus was not specifically stained. However ,  both the dura 
and ependyma were only partially blocked suggesting the 
possibility of a modest amount of APM in those tissues. 
The pituitary showed blockable staining in all three lobes 
at 1/1,000 tlter (Fig. 6A and a). In the posterior pituitary the 
staining again appeared to be associated with vasculature. In 
the intermediate lobe only its surface was immunopositive. 
Small regions of patchy lmmunoreactivity,  apparently at the 
cell surface, were seen in the anterior lobe. In the liver fine 
cell surface staining could be detected between parenchymal 
cells (Fig. 6D). In the rat ileum the entire lumen was posi- 
tively stained over the surface of the villus projections (Fig. 
6B). In the kidney two specific staining patterns could be 
seen (Fig. 6C). One is a very heavy proximal tubular stam 
and the second is a lighter more central tubular stain. No 
glomeruli were stained. In the adrenal medulla patches of 
APM were detected (Fig. 6E) in the cortex a lower level of 
staining was also seen. 
DISCUSSION 
The results of these studies clearly demonstrate that 
aminopeptidase M activity in rat brain is localized primarily 
if not exclusively on blood vessels. Beyond this vascular 
pattern in the brain the localization of APM on proximal 
tubules in the kidney, between parenchymal cells of the 
liver, on some cell surfaces in the anterior pituitary and ad- 
renal medulla, on the luminal surface of the small gut- -a l l  
suggest a unique physiological role for APM. In each case 
this enzyme is localized so that it can limit diffusion of pep- 
tides across certain barriers. The broad substrate specificity 
of amlnopeptidase M is consistent with its role in hydrolyz- 
ing a broad spectrum of peptlde substrates which differ 
amongst different tissues. APM in brain vessels might limit 
contact between blood born materials and neurons; in kidney 
APM in the tubules may degrade peptides and thereby pre- 
vent their reentry into the vasculature. In the gut, APM on 
the surface of the lumen might also control access of con- 
sumed substances to the vasculature. In a similar fashion 
APM on liver parenchyma, adrenal medulla and anterior pi- 
tuitary cell surface may help limit peptide diffusion through 
these sinusoidal systems. It should be noted that APM's  vas- 
cular localization in other tissues has previously been 
demonstrated [19]. 
Given this general distribution pattern, the evidence that 
aminopeptidase M acts as an "enkephahnase"  in brain must 
be reconciled with its barrier type localization. It has been 
assumed that the analgesic effect of the aminopeptidase in- 
hibitor bestatin is directly related to its inhibition of the 
enzyme [8,9]. Inhibition of the enzyme would decrease the 
rate at which endogenously released enkephalins are inac- 
tivated. Enkephalin levels would mcrease,  which in turn 
would lead to a greater occupancy of enkephalin receptors.  
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bestatin increases the level of intact enkephalin which can be 
recovered after potassium depolarization of brain slices [5,6] 
or after substance P induced enkephalin release from rat 
spinal cord [4]. A tacit assumption of this model is that the 
enkephalin degrading peptidases which act as 
"enkephalinases" in v tvo  are located at synaptlc clefts be- 
tween enkephalinergic neurons analogous to the localization 
of acetylcholinesterase at cholinergic synapses. 
The current light microscopic study offers little support 
for aminopeptidase M localization in the neuropfle and there- 
fore does not support synaptm region localization. The 
heavily vascular localization in the brain reported here ~s a 
very broad CNS pattern and ~s not distributed in a fashion 
unique to OplOld receptors or enkephalin terminals. It has in 
fact been seen in all brain areas studied and has been shown 
to be an enzyme with rather broad peptide actions [19]. Thus 
the model that enkephalin degrading peptidases which act as 
"enkephalinases" m v~vo are located at enkephalinergic 
synapses is not supported by this study. Instead a model in 
which enkephalins diffuse away from enkephalinergic 
synapses and are then degraded distal to the receptor ap- 
pears more consistent with our findings. 
The neutral endopeptidase called "enkephalinase" has 
also been lmphcated as acting as an "enkephalinase" m v tvo  
[12, 21, 22]. This enzyme has recently been found to be 
localized on glial cells and not on neurons [15,16]. Thus, like 
amlnopeptldase M, this enzyme could not easily exert its 
"enkephahnase" action directly at enkephallnergic 
synapses. 
The question that remains to be answered is how the 
enkephalin degrading peptidases can act as "enkepha- 
linases" in v t v o ,  and yet be located outside enkephallnerglc 
synapses. One possibility is that a minor fraction of these 
enzymes does in fact exist m the neuropile at 
enkephalinergm synapses. If only a small fraction of APM 
was located at enkephahn synapses it is unlikely that the 
current methods could detect it. Multiple forms of the neu- 
tral endopeptidase "enkephallnase" have been observed 
[7,20], and one of these subforms could represent a synapse 
specific form of the enzyme. However no such multiple 
forms of aminopeptidase M have been reported, and no evi- 
dence that the multiple "enkephalinase" forms have differ- 
ent cellular locahzatlon has been obtained. 
A model that can be considered is one in which the levels 
of synaptically released enkephahns exceed that reqmred by 
the enkephalin receptors. Diffusion of free enkephalin away 
from the vlCinlty of its receptor might reduce its concentra- 
tion below the Kd of the receptor. However, the extracellu- 
lar space through which the enkephalins diffuse is of a lim- 
ited finite volume. The concentration of free enkephalins 
would initially be rapidly decreased as they move through a 
large concentration gradient, but would remain relatively 
high as the concentration of free enkephalins distal to the 
receptor increases. The resultant effect would be a pool of 
free enkephallns which exists for a relatively large time in the 
vicinity of enkephahn receptors. However, if enkephalin de- 
grading peptidases act m proximity to enkephalinergic 
synapses the diffusion of enkephalins away from their recep- 
tor would be facilitated by the maintenance of a large con- 
centratlon gradient. The function of "enkephalinases" thus 
m i g h t  be  to maintain a concentration gradient to ensure the 
efficient diffusion of enkephalins away from their receptors. 
The functioning of peptidases in this manner would ex- 
plain how they serve as "enkephalinases" with their lo- 
calization being distal to enkephalinerglc synapses. In addi- 
tion, the lack of specificity known to exist in all of the pep- 
tidases believed to act as "enkephalinases" m vivo would 
not be inconsistent with such a model. The action of these 
peptldases distal to enkephahnerglc receptors would not re- 
quire the high degree of specificity seen in an enzyme such as 
acetylcholinesterase, and would permit these peptidases to 
service a variety of peptiderglc systems. For example 
angiotensm converting enzyme [12,21] and the enkephalln 
degrading aminopeptldases M and MII [14] hydrolyze opioid 
as well as non-opioid peptides. The neutral endopeptidase 
"enkephalinase" acts on a variety of opiold as well as non- 
oploid peptldes [14] and it has been proposed that this 
enzyme is the major substance P degrading peptldase in 
brain [18]. 
Thus we propose that "enkephalinases" function not by 
reactivating enkephalins at enkephallnergic synapses, but 
rather in rough proximity to these synapses. The role of 
these peptldases may be to faclhtate the diffusion of 
enkephalins away from their receptors. 
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FACING PAGE 
FIG 6. Several other tissues showed signs of specific APM staining at 1/1,000. pituitary (A, a); ileum (B, b), kidney (C, c), liver (D, d), and 
adrenal medulla (E, e) The positive stains are seen in panels indicated by capital letters and the APM blocked controls by panel with lower 
case letters Blocking was carried out at 12.5 p.g of APM protein (all cahbratIon bars= 100/xm) Panels A and a All three lobes of pituitary show 
specific APM staining. In the posterior lobe (P) it seems to be mainly vascular In the intermediate lobe (I) it is on the superficial aspects of the 
lobe. In the anterior lobe (A) scattered positive structures are seen. Panels B and b The superficial aspect of the villus processes (projecting 
into the gut lumen) of Ileum shows strong positive APM staining (single arrow) Double arrows point to unblocked RBCs. Panels C and c The 
inner aspect of proximal tubules of the kidney were heavily positive (single arrow) for APM, but glomeruli were not. Panels D and d: Liver 
parenchymal cells (single arrow) show specific stains in the region of cell-cell contacts. Double arrows indicate non-specific residual 
peroxldase staining in red cells Panels E and e: Adrenal medullary cells (single arrow) showed specific cell surface staining. Double arrows 
indicate non-specific peroxidase staining. 
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